BioStock: Saniona begins 2022 with three clinical trials ongoing

During 2021 Saniona succeeded in the feat of initiating three clinical trials. One phase I study with SAN711 for the treatment of rare neuropathic disorders and two phase IIb trials with Tesomet, one for the treatment of hypothalamic obesity and one  for the treatment of Prader Willi Syndrome. With these three trials up and running Saniona is gearing up in the overall ambition to become a globally acclaimed, fully integrated pharmaceutical company. BioStock contacted Rami Levin, President and CEO of Saniona, who shares his expectations for 2022.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/01/saniona-begins-2022-with-three-clinical-trials-ongoing/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se